NORDIC NANOVECTOR ASA – SALE OF SHARES BY MANAGEMENT MEMBER
Jostein Dahle, who is the Chief Scientific Officer of Nordic Nanovector ASA (the “Company”), has on 20 January 2015 sold 4,000 shares in the Company at a price of NOK 32 per share. Following the share sale, Mr Dahle holds 264,358 shares in the Company.
The shares were sold to finance the purchase price and strike price for shares already acquired, and tax relating to share acquisitions and sales.
Luigi Costa, CEO
Cell: (41) 79 124 8601
Fax: (47) 22 58 00 07
E-mail: lcosta@nordicnanovector.com
Tone Kvåle, CFO
Cell: (47) 91 51 95 76
Fax: (47) 22 58 00 07
E-mail: tkvale@nordicnanovector.com
About Nordic Nanovector ASA (ticker: NANO on NOTC)
Nordic Nanovector ASA is a privately held company established in 2009. The company is developing innovative radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other difficult to treat cancers. Nordic Nanovector intends to commercialise its product candidates through strategic alliances and partnerships with experienced oncology businesses and by establishing its own sales and marketing capabilities in selected markets. The company is based and has offices and laboratories in Oslo, Norway.
The company’s lead product candidate, Betalutin™, is a radioimmunotherapeutic that aims to prolong and improve the quality of life of people who suffer from NHL. Further information can be found at: www.nordicnanovector.com.
Tags:
